FTSJ3 and cancer: Studies have found that FTSJ1 and MRM2 have no effect on the in vivo screening of shRNA in most tumour cells [15, 16]; however, FTSJ3 is commonly amplified and overexpressed in malignant tumours, such as breast cancer.